Johnson & Johnson is the 16th drug manufacturer to impose conditions on 340B pricing when hospitals use contract pharmacies.

News Alert

Johnson & Johnson Becomes the 16th Drug Manufacturer to Restrict 340B Contract Pharmacy

Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies. Grantees are exempt from the requirements, which take effect May 2.

J&J’s mid-day notice to customers made it the 16th manufacturer to adopt such a policy. It came less than a week after Gilead announced restrictions on 340B pricing on its branded hepatitis C treatments when hospital and grantee covered entities use contract pharmacies. This is a developing story. We will have in-depth coverage of J&J’s new policy in Tuesday’s issue.

Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report